Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO i study

American Heart Journal

Volumn 169, Issue 6, 2015, Pages 906-915.e13

  Kereiakes, Dean J ^a   Robinson, Jennifer G ^b   Cannon, Christopher P ^c   Lorenzato, Christelle ^d   Pordy, Robert ^e   Chaudhari, Umesh ^d   Colhoun, Helen M ^f  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d SANOFI   (France)

^e REGENERON PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; ROSUVASTATIN; SIMVASTATIN; ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADD ON THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR;

ANTIBODIES; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84930179904     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.03.004     Document Type: Article

References (12)

1. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. S.M. Boekholdt, G.K. Hovingh, and S. Mora Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials J Am Coll Cardiol 64 2014 485 494
3. S.M. Boekholdt, B.J. Arsenault, and S. Mora Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
4. D. Morrone, W.S. Weintraub, and P.P. Toth Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials Atherosclerosis 223 2012 251 261
5. S.C. Smith Jr., and S.M. Grundy 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol J Am Coll Cardiol 64 2014 601 612
6. J.M. McKenney, M.J. Koren, and D.J. Kereiakes Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
7. E.M. Roth, J.M. McKenney, and C. Hanotin Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
8. E.M. Roth, M.R. Taskinen, and H.N. Ginsberg Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial Int J Cardiol 176 2014 55 61
9. E.A. Stein, D. Gipe, and J. Bergeron Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
10. H.M. Colhoun, J.G. Robinson, and M. Farnier Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials BMC Cardiovasc Disord 14 2014 121
11. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
12. D.J. Blom, T. Hala, and M. Bolognese A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819